author-photo

Konstantinos Tsaparikos

Pfizer

21

Papers

760

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice

2018 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (19)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

2015 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (170)
Abstract A43: RB pathway disruption by the CDK4/6 inhibitor palbociclib enhances responses to chemotherapy in squamous cell lung cancer

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A2-33: Molecular profiling of patient-derived xenograft models across cancers

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

2015 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (289)
Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (8)
Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (12)
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

2013 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (29)